Academic Journal
A Multi-Institutional Experience of Proton Beam Therapy for Sinonasal Tumors
| Title: | A Multi-Institutional Experience of Proton Beam Therapy for Sinonasal Tumors |
|---|---|
| Authors: | Nathan Y. Yu, MD, Mauricio E. Gamez, MD, William F. Hartsell, MD, Henry K. Tsai, MD, George E. Laramore, MD, PhD, Gary L. Larson, MD, Charles B. Simone, II, MD, Carl Rossi, MD, Sanford R. Katz, MD, Matthew R. Buras, MS, Michael A. Golafshar, MS, Carlos E. Vargas, MD, Samir H. Patel, MD |
| Source: | Advances in Radiation Oncology, Vol 4, Iss 4, Pp 689-698 (2019) |
| Publisher Information: | Elsevier, 2019. |
| Publication Year: | 2019 |
| Collection: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Purpose: To report the outcomes of sinonasal tumors treated with proton beam therapy (PBT) on the Proton Collaborative Group registry study. Methods and Materials: Sixty-nine patients with sinonasal tumors underwent curative intent PBT between 2010 and 2016. Patients who received de novo irradiation (42 patients) were analyzed separately from those who received reirradiation (27 patients) (re-RT). Median age was 53.1 years (range, 15.7-82.1; de novo) and 57.4 years (range, 31.3-88.0; re-RT). The most common histology was squamous cell carcinoma in both groups. Median PBT dose was 58.5 Gy (RBE) (range, 12-78.3; de novo) and 60.0 Gy (RBE) (range 18.2-72.3; re-RT), and median dose per fraction was 2.0 Gy (RBE) for both cohorts. Survival estimates for patients who received de novo irradiation and those who received re-RT were calculated using the Kaplan-Meier method. Results: Median follow-up for surviving patients was 26.4 months (range, 3.5-220.5). The 3-year overall survival (OS), freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence (FFLR) for de novo irradiation were 100%, 84.0%, 77.3%, and 92.9%, respectively. With re-RT, the 3-year OS, freedom from distant metastasis, FFDP, and FFLR were 76.2%, 47.4%, 32.1%, and 33.8%, respectively. In addition, 12 patients (17.4%) experienced recurrent disease. Re-RT was associated with inferior FFLR (P = .04). On univariate analysis, squamous cell carcinoma was associated with inferior OS (P |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2452-1094 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2452109419300922; https://doaj.org/toc/2452-1094 |
| DOI: | 10.1016/j.adro.2019.07.008 |
| Access URL: | https://doaj.org/article/ee6b8c11f16f49d089c23ecd99226265 |
| Accession Number: | edsdoj.6b8c11f16f49d089c23ecd99226265 |
| Database: | Directory of Open Access Journals |
| ISSN: | 24521094 |
|---|---|
| DOI: | 10.1016/j.adro.2019.07.008 |
| Published in: | Advances in Radiation Oncology |
| Language: | English |